{"id":"nct:NCT00161811","kind":"trial","title":"Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005","authors":["Alachua Government Services, Inc."],"author_count":1,"year":2005,"published":"2005-09-13","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT00161811","source_url":"https://clinicaltrials.gov/study/NCT00161811","archive_url":"https://space-kitty.com/papers/nct:NCT00161811","updated":"2015-10-09","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Influenza"],"details":{"acronym":null,"status":"COMPLETED","phase":"PHASE2, PHASE3","study_type":"INTERVENTIONAL","enrollment":1400,"sponsor":"Alachua Government Services, Inc.","conditions":["Influenza"],"interventions":["BIOLOGICAL: Vero Cell-derived Influenza Vaccine","BIOLOGICAL: Egg cell-derived Influenza Vaccine"],"start_date":"2004-11-01","start_date_type":null,"primary_completion_date":null,"has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}